News and Comments

The Biotech Sector Evolution in the News

  Wednesday, June 22, 2016

Innoviva (INVA) and GlaxoSmithKline plc (GSK) announced positive results from the pivotal Phase 3 FULFIL study of the Closed Triple combination of fluticasone furoate, umeclidinium, and vilanterol) for patients with chronic obstructive pulmonary disease (COPD).  More...

SPARK Therapeutics History Foretells Its Triumph in Gene Therapy

  Thursday, June 16, 2016

SPARK More...

Good News for Agenus and for Global Blood Therapeutics

  Friday, June 10, 2016

Agenus (AGEN) announced that a lead product candidate is selected under its license and research collaboration with Merck, which is known as MSD outside the United States and Canada.   More...

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

  Thursday, June 02, 2016

Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) means more than pressuring the FDA to approve Sarepta’s DMD product eteplirsen.  More...

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

  Friday, May 27, 2016


Great News for Innoviva and COPD Patients

  Wednesday, May 25, 2016

GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) Demonsterates Superiority Over Usual Care. More...

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

  Monday, May 23, 2016

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).  More...

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

  Tuesday, May 17, 2016


Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

  Friday, May 13, 2016

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.  More...

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

  Monday, May 09, 2016


Recent Postings



Sangamo (SGMO) Dynavax (DVAX) Sarepta (SRPT) Sanofi (SNA) Editas (EDIT) AERIE PHARMACEUTICALS Prosensa (RNA) AGOS (ARGS) Illumina (ILMN) Inovio (INO) Tysabri Jazz Pharmaceuticals (JAZZ) galapagos (GLPG) BIOMARIN (BMRN) HALOZYME (HALO) Rapamune KERYX (KERX) ADVENTRIX (ANX) Merck (MRK) Agenus (AGEN INNOVIVA (INVA) Alder Biopharmaceuticals (ALDR) SERES THERAPEUTICS (MCRB) Spike Therapeutics (ONCE) Mirati Therapeutics (MRTX) Roche (ROCHE) Alnylam (ALNY) Incyte (INCY) Intrexon (XON) Roche (RHHBY) Bristol-Myers Squibb (BMY) Xoma (XOMA) ARGOS (ARGS) Ionis (IONS) Aimmune Therapeutics (AIMT) Vertex (VRTX) TOKAI (TKAOI) Elan (ELN) GlaxoSmithKline (GSK) Telaprevir Herceptin Biogen Idec (BIIB) Seattle Genetics (SGEN) Ridaforolimus Intercept (ICPT) Zerenex Galena (GALE) Sanofi (SNY) JUNO (JUNO) Theravance (THRX) Cytokinetics (CYTK) OSI (OSIP) ISIS (ISIS) Onyx (ONXX) Revlimid (lenolidamide) Sanofi-Aventis (SAN) Abbott Laboratories (ABT) Micromet (MITI) ARCA (ABIO) Valeant Pharmaceuticals International (VRX) Sequenom (SQNM) Regeneron (REGN) Velcade (bortezomib) C4 Therapeutics Endometrial Cancer ZALTRAP™ Vitae Pharmaceuticals (VTAE) Biocryst (BCRX) SUNESIS PHARMACEUTICALS (SNSS) ABBVIE (ABBV) Pluristem (PSTI) PTC Therapeutics (PTCT) Auspex (ASPX) Benlysta (belimumab) Exelixis (EXEL) GUARDIAN HEALTH Agenus (AGEN) Dendreon (DNDN) KITE (KITE) Anadys (ANDS) CompuGen (CGEN) ACADIA (ACAD) SYNTA (SNTA) REGULUS (RGLS) Idenix (IDIX) NANTKWEST (NK) Human Longevity (HLI) Ariad (ARIA) Genentech Multiple Myeloma Anacor (ANAC) VANDA (VNDA) Amgen (AMGN) ImmunoGen (IMGN) Global Cell Therapeutics (GBT) Intermune (ITMN) NEKTAR (NKTR)) Trastuzumab-DM1 RenenxBio (RGNX) Gilead (GILD) Theravance Bio Pharma (TBPH) IDERA (IDRA) Ziofpharm (ZIOP) Prolor Biotech (PBTH) Human Genome Sciences (HGSI) Array Pharmaceuticals (ARRY)